| Q33887878 | A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. |
| Q40916525 | Cleavage of urokinase receptor regulates its interaction with integrins in thyroid cells. |
| Q40893088 | Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin |
| Q73685074 | Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients |
| Q35764327 | Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue |
| Q40900712 | Generation of high-affinity rabbit polyclonal antibodies to the murine urokinase receptor using DNA immunization |
| Q42462623 | Immunohistochemical identification of the receptor for urokinase plasminogen activator associated with fibrin deposition in normal and ectopic human placenta |
| Q47344852 | Increase of a urokinase receptor-related low-molecular-weight molecule in colorectal adenocarcinomas |
| Q43811861 | Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat |
| Q24683196 | Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction |
| Q41064411 | Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect |
| Q24302483 | Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G |
| Q51221037 | Requirement of the enzymatic and signaling activities of plasmin for phorbol-ester-induced scattering of colon cancer cells. |
| Q73898135 | Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo |
| Q36619635 | Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies. |
| Q36046670 | The Urokinase Receptor Can Be Induced byBorrelia burgdorferithrough Receptors of the Innate Immune System |
| Q34009345 | The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. |
| Q74121187 | The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction |
| Q33538432 | The urokinase plasminogen activator system as a target for prognostic studies in breast cancer |
| Q41522331 | The urokinase-type plasminogen activator system in cancer metastasis: A review |
| Q34089936 | Tumour microenvironments induce expression of urokinase plasminogen activator receptor (uPAR) and concomitant activation of gelatinolytic enzymes |
| Q33948206 | Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. |
| Q43000092 | Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. |
| Q28350698 | Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo |
| Q71171008 | Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness |
| Q34489359 | Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis |
| Q38609665 | Urokinase-type plasminogen activator receptor is internalized by different mechanisms in polarized and nonpolarized Madin-Darby canine kidney epithelial cells |
| Q41591661 | uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? |